China News Service, Guangzhou, August 11 (Cai Minjie, Lin Zhiwei) Lung cancer is one of the fastest growing malignancies in the Mainland in terms of morbidity and mortality, and about 85% of them are non-small cell lung cancer.

Wu Yilong, life director of Guangdong Provincial People's Hospital and honorary director of Guangdong Lung Cancer Research Institute, said recently that the latest study found that adjuvant targeted therapy after early and mid-stage lung cancer surgery can reduce the risk of recurrence and brain metastasis in patients.

　　Data show that the 5-year survival rate of lung cancer patients diagnosed and treated early can reach more than 90%.

Lobectomy and mediastinal lymph node resection are currently commonly used and effective surgical methods for patients with early and mid-stage lung cancer.

　　With the widespread application of thoracoscopic lobectomy surgery in the Mainland, the overall level of minimally invasive thoracic surgery in the Mainland has led the world. Up to 30% of patients with non-small cell lung cancer can be diagnosed at an early stage and undergo potential radical surgery, especially for For early-stage lung cancer patients with tumors less than 1 cm, after surgery, the 5-year survival rate can reach more than 90%.

　　Although early detection and surgery are curative means to achieve early and mid-stage lung cancer, nearly half of patients diagnosed as early stage and more than three-quarters of patients diagnosed as advanced stage experience recurrence within five years after surgery.

　　"There are generally two risks after early lung cancer surgery, one is local recurrence, and the other is distant metastasis." Zhong Wenzhao, director of the Guangdong Lung Cancer Institute, said that local recurrence refers to the area around the tumor, including the ipsilateral thoracic cavity. The local recurrence around the primary tumor and the drainage area within the primary tumor. This local recurrence is likely to be caused by the failure of the operation; distant metastasis means that the tumor has left the original site and moved to other organs, including the brain, bones, and other organs. Recurrence of spread of liver, kidney, adrenal glands and other organs.

　　Wu Yilong said: "Recurrence and metastasis are huge problems faced by patients, family members, and clinicians after NSCLC patients undergo surgery. According to all our current statistics, we can see that if it is a relatively advanced patient, such as stage II, III In patients with early stage, the rate of recurrence or metastasis within about two years after surgery is as high as 60% to 70%. Therefore, how to control the recurrence or metastasis within two years is the focus of our consideration."

　　With the continuous advancement of medical standards, the emergence of adjuvant targeted therapy options for patients with EGFR gene mutation-positive lung cancer diagnosed in the early and mid-term has brought new hope for the long-term and high-quality survival of China's early and mid-term lung cancer patients.

　　"In the past, chemotherapy had very low therapeutic effects on brain metastases, but now the third-generation EGFR-targeted drugs have very good brain function, so this is a very significant breakthrough." Wu Yilong said, different from adjuvant chemotherapy and radiotherapy, Adjuvant targeted therapy can specifically act on certain specific sites of tumor cells, highly selective killing tumor cells without killing or only seldom injuring normal cells.

　　Experts remind that in addition to standard treatment for early and mid-stage lung cancer patients, attention should also be paid to postoperative follow-up.

Patients should be followed up regularly in accordance with the doctor's advice, and the high-incidence parts of the abdomen, brain, bones and other parts that are prone to distant metastasis of the whole body should be the focus of the review, and appropriate follow-up treatment plans should be adopted in time.

(Finish)